

Auxesis Pharma Holding AB (publ)

Capitalisation Table and Investment Overview | September 2026 | Company registration no. 559195-6486

Investment proposition Auxesis Pharma is developing the Pain Block™ platform for rapid, localised and non-systemic treatment of skin pain and irritation, supporting multiple pharmaceutical and dermatology products from one technology base.

OWNERSHIP STRUCTURE

Shareholder category	Stake	Description
Founder	58.4%	Founder and business developer within the Auxesis Group since 2015.
Other shareholders	41.6%	Primarily private individuals and smaller companies.

Approximately 800 shareholders. Source: Euroclear Sweden share register as at 30 June 2026.

PLANNED USE OF PROCEEDS

Area	Share	Purpose
Clinical development	20%	Clinical trials, regulatory activities and market approval.
Product development	20%	Pipeline and formulation development.
Business development	15%	Partnerships, manufacturing and supply chain.
Working capital	15%	Organisational growth, key hires and operations.
IP and regulatory	15%	Patent protection and regulatory approvals.
Commercial readiness	15%	Market access and launch preparation.

OUR MISSION

Improving quality of life for people living with skin disorders.

Illustrative information based on current assumptions and pitch material dated 5 August 2026. This document is not an offer of securities or investment advice. Financing terms and market figures should be independently verified.

FINANCING STRATEGY

5,824,569 Class A shares outstanding. The current issue comprises up to 400,000 new Class B shares, each with one tenth (1/10) of the voting rights of a Class A share. The AGM has authorised up to 1,000,000 Class B shares in total until the 2027 Annual General Meeting.

Financing round	Series A
Target raise	Up to SEK 40 million
Indicative equity offered	Up to 20%
Target runway	36 months
Ongoing tranche	Up to SEK 24.6 million
Subscription price	SEK 82 per Class B share
Latest stated valuation	SEK 650 million
Capital invested to date	More than SEK 80 million

Final pricing, share count, valuation basis and dilution should be reconciled and approved before external distribution.

CONTACT

Auxesis Pharma Holding AB (publ) | auxesis@auxesispharma.com | www.auxesis.se